In Silico Biosciences

Inspiring Discovery | Guiding Results

CNS quantitative systems pharmacology is based on the realization that human pathology is driven by a network imbalance rather than deficits at a single target or gene.

Computer-based modeling of biophysically realistic neuronal network circuits calibrated with human imaging and clinical data is a translational tool to assess the outcome of therapeutic interventions in complex brain circuits. ISB provides insights into the systemic behavior at each R&D stage in high impact decision processes.

In Silico Biosciences is an innovator in predictive, computer-based mechanistic models that support drug discovery for chronic pain and diseases of the central nervous system and development of clinical tools to address unmet needs of patients with chronic pain.

Today, after two decades of drug discovery support for the pharmaceutical industry, we are proud to build on our legacy by focusing our core strengths on pain drug discovery and on tools for clinician use in prescribing safe and effective precision therapies that make a difference for patients with chronic pain.

Inspired by patients who suffer from chronic pain and motivated by the dedicated clinicians who manage their care, our goal is to offer an expanded range of treatment options to produce improved patient outcomes and heightened patient satisfaction.

QSPainRelief Consortium

ISB is a founding member of the QSPainRelief Consortium, a five-year, $6,000,000 pharmacological pain relief project. Academic and industry leaders in chronic pain, pharmacology, pharmacogenomics, personalized medicine, systems biology, and predictive biophysical computer modeling combined their expertise in a consortium partnership to develop validated computational models to optimize the personalized treatment of chronic pain.

Robert Carr, ISB’s Chairman and CEO, delivers a presentation at the 5th General Assembly of the QSPainRelief Consortium.

ISB Presentation_5th General Assembly_QSPainRelief_2023.12.6-8